DigitalOcean Reaffirms Commitment to Quality Excellence in Cloud Services Government Plans Major Overhaul of Tax Administration for Smooth GST Implementation Nvidia Shares Dip PostEarnings Why Some Market Participants May Be Overlooking Key Factors Goldman Sachs Reportedly Selected to Lead SpaceX IPO in Potential Landmark Market Debut Beyond Inc Acquires Buy Buy Baby Brand Rights Reuniting Iconic Retail Names Brigade Enterprises to Develop Premium Residential Project in Hyderabad with Estimated Revenue of 850 Crore WTTR Q1 2026 Earnings Earnings Per Share Soars Past Estimates with 106 Surprise Home Depot Q1 2026 Earnings EPS Misses Estimates Amid Mixed Operating Trends ECCX Q1 2026 Earnings EPS Misses Estimates Slightly Notes Decline Marginally IBTA Q1 2026 Earnings EPS Misses Estimates Stock Edges Higher VNCE Q1 2026 Earnings Massive EPS Beat Surprises Market Despite Revenue Gap iRhythm Holdings IRTC Slides 19 as Stock Tests Key Support Zone Vantage Corp VNTG Surges 7 as Momentum Builds Toward Key Resistance Strategy Inc Preferred Stock STRC Holds Steady Near Support Amid Low Volatility Seres Therapeutics MCRB Declines 593 as Selling Pressure Intensifies Kymera Therapeutics KYMR Slips Over 2 as Biotech Shares Retreat Support Levels in Focus BofA Adjusts Royal Gold Price Target Amid Reduced Hod Maden Stake CIFR Q1 2026 Earnings EPS Misses Estimates Amid Operational Challenges Stock Rises 209 Roadzen Inc Warrants RDZNW Fall Sharply as Selling Pressure Intensifies IT Tech Packaging Q3 2025 Earnings Reports Net Loss Per Share of 011 Shares Dip Post Holdings Q1 2026 Earnings Strong EPS Beat Amid Unclear Revenue Picture ADPT Q1 2026 Earnings EPS Beat Driven by Cost Discipline and Operational Progress Voyager Therapeutics Inc VYGR Q1 2026 Earnings Narrowed Loss and Pipeline Progress Support Positive Market Reaction ADIL Q1 2026 Earnings Surprise EPS Beat Amid PreRevenue Phase Stock Drops 957 Leggett Platt Q1 2026 Earnings EPS Misses Estimates as Profitability Pressures Persist SRPT Q1 2026 Earnings EPS Smashes Estimates by 1847 as Gene Therapy Execution Drives Profit Surprise